2-benzyl-N-cyclohexylimidazo[1,2-a]pyrazin-3-amine | 1401520-21-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 英文名称: 2-benzyl-N-cyclohexylimidazo[1,2-a]pyrazin-3-amine
• CAS: 1401520-21-5
• 化学式: C₁₉H₂₂N₄
• 分子量: 306.41
• InChiKey: OLTYIBGABORSGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氨基吡嗪 、 异氰环已烷 、 苯乙醛 在 盐酸 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 0.33h， 以50%的产率得到2-benzyl-N-cyclohexylimidazo[1,2-a]pyrazin-3-amine
  参考文献：
  名称：

  Antibacterial activities of Groebke–Blackburn–Bienaymé-derived imidazo[1,2-a]pyridin-3-amines

  摘要：

  We sought to explore the imidazo[1,2-a]pyridin-3-amines for TLR7 (or 8)-modulatory activities. This chemotype, readily accessed via the Groebke-Blackburn-Bienayme multi-component reaction, resulted in compounds that were TLR7/8-inactive, but exhibited bacteriostatic activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). To investigate the mechanism of antibacterial activity of this new chemotype, a resistant strain of S. aureus was generated by serially passaging the organism in escalating doses of the most active analogue. A comparison of minimum inhibitory concentrations (MICs) of known bacteriostatic agents in wild-type and resistant strains indicates a novel mechanism of action. Structure-activity relationship studies have led to the identification of positions on the scaffold for additional structural modifications that should allow for the introduction of probes designed to examine cognate binding partners and molecular targets, while not significantly compromising antibacterial potency. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.052

文献信息

• [EN] SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF<br/>[FR] INHIBITION PAR DES PETITES MOLÉCULES DU FACTEUR DE TRANSCRIPTION SALL4 ET SES UTILISATIONS
  申请人：DANA FARBER CANCER INST INC

  公开号：WO2019070943A1

  公开（公告）日：2019-04-11

  Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.

  本文提供了一些干扰SALL4功能的化合物。同时还描述了这些化合物的药物组合物和医疗用途。
• Small molecule inhibition of transcription factor SALL4 and uses thereof
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US11530209B2

  公开（公告）日：2022-12-20

  Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.

  本文提供了能干扰 SALL4 功能的化合物。还描述了这些化合物的药物组合物和医疗用途。
• SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20200317664A1

  公开（公告）日：2020-10-08

  Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.